<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917876</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL130702</org_study_id>
    <nct_id>NCT02917876</nct_id>
  </id_info>
  <brief_title>Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy</brief_title>
  <acronym>Predictors</acronym>
  <official_title>Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Miriam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Miriam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to understand the physical, physiologic and biologic features that
      predispose a woman to the development of obstructive sleep apnea once they are exposed to the
      cardiopulmonary and metabolic physiological changes of pregnancy. Knowing these specific
      predictive factors can help identify a population at risk and guide clinicians to develop
      suitable targeting screening strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited from multiple community and hospital-based practices that care for
      pregnant women. Subjects will have:

        1. measurements of body composition

        2. anthropometric measures

        3. sleep and mood questionnaires

        4. Home sleep studies

        5. blood testing for biological markers

        6. salivary testing for hormonal markers

        7. pulmonary function tests and upper airway patency measurements

      Women without sleep apnea at enrollment will then be followed longitudinally for the
      development of obstructive sleep apnea during pregnancy with repeat assessment during their
      third trimester. Women diagnosed with sleep apnea at enrollment will have no further
      assessment in late pregnancy.

      Monetary incentives will also be issued at data collection points. Subjects will receive
      small gift incentives such as baby-related items.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristics of participants who develop obstructive sleep apnea defined as an apnea hypopnea index &gt;5 events per hour</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>The study will develop a model of biologic, physiologic and anthropometric measures that predict the development of obstructive sleep apnea apnea later in pregnancy compared to baseline in early pregnancy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Pregnancy</condition>
  <condition>Obesity</condition>
  <condition>Sleep</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be stored for future testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women, 18 years or older, at less than 13 completed weeks of gestation and who
        have a BMI that is greater than 30 kg/m2 at recruitment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;13 completed weeks of gestation

          -  BMI &gt;30 kg/m2 at recruitment

          -  &gt;18 years of age

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Unable to meet inclusion criteria

          -  Twin pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada Bourjeily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Miriam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Allenson, MS</last_name>
    <phone>401-793-3879</phone>
    <email>Christine.Allenson@Lifespan.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghada Bourjeily, MD</last_name>
    <phone>401-444-8664</phone>
    <email>ghada_bourjeily@brown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Allenson, MS</last_name>
      <phone>401-793-3879</phone>
      <email>Christine.Allenson@Lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Ghada Bourjeily, MD</last_name>
      <phone>401-444-8664</phone>
      <email>ghada_bourjeily@brown.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Miriam Hospital</investigator_affiliation>
    <investigator_full_name>Ghada Bourjeily</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Obesity</keyword>
  <keyword>Fluid shifts</keyword>
  <keyword>Body composition</keyword>
  <keyword>Sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data for primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Investigators data access requests will be reviewed by an independent review committee. Requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

